Your browser doesn't support javascript.
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso, Fabio Salvatore; Giuliano, Alessandra; Fries, Walter; Viola, Anna; Abbruzzese, Alfredo; Cappello, Maria; Giuffrida, Enrica; Carrozza, Lucio; Privitera, Antonino Carlo; Magnano, Antonio; Ferracane, Concetta; Scalisi, Giuseppe; Minissale, Maria Giovanna; Giangreco, Emiliano; Garufi, Serena; Bertolami, Carmelo; Cucinotta, Ugo; Graziano, Francesco; Casà, Angelo; Renna, Sara; Teresi, Giulia; Rizzuto, Giulia; Mannino, Mariella; Maida, Marcello; Orlando, Ambrogio.
  • Macaluso FS; Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
  • Giuliano A; Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
  • Fries W; Inflammatory Bowel Disease Unit, Policlinico "G. Martino," Messina, Italy.
  • Viola A; Inflammatory Bowel Disease Unit, Policlinico "G. Martino," Messina, Italy.
  • Abbruzzese A; Inflammatory Bowel Disease Unit, Policlinico "G. Martino," Messina, Italy.
  • Cappello M; Gastroenterology and Hepatology Section, Promise, University of Palermo, Palermo, Italy.
  • Giuffrida E; Gastroenterology and Hepatology Section, Promise, University of Palermo, Palermo, Italy.
  • Carrozza L; Gastroenterology and Hepatology Section, Promise, University of Palermo, Palermo, Italy.
  • Privitera AC; Inflammatory Bowel Disease Unit, "Cannizzaro" Hospital, Catania, Italy.
  • Magnano A; Gastroenterology Unit, Policlinico "Vittorio Emanuele," Catania, Italy.
  • Ferracane C; Gastroenterology Unit, Policlinico "Vittorio Emanuele," Catania, Italy.
  • Scalisi G; Gastroenterology Unit, A.R.N.A.S. "Garibaldi," Catania, Italy.
  • Minissale MG; **Gastroenterology and Endoscopy Unit, "Buccheri La Ferla Fatebenefratelli" Hospital, Palermo, Italy.
  • Giangreco E; Gastroenterology Unit, "Guzzardi" Hospital, Vittoria, Italy.
  • Garufi S; Gastroenterology Unit, "S. Elia- M. Raimondi" Hospital, Caltanissetta, Italy.
  • Bertolami C; Gastroenterology Unit, "Papardo Piemonte" Hospital, Messina, Italy.
  • Cucinotta U; Pediatric Gastroenterology and Cystic Fibrosis Unit, University of Messina, Messina, Italy.
  • Graziano F; Pediatric Gastroenterology and Cystic Fibrosis Unit, University of Messina, Messina, Italy.
  • Casà A; Pediatric Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
  • Renna S; Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
  • Teresi G; Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
  • Rizzuto G; Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
  • Mannino M; Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
  • Maida M; Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
  • Orlando A; Gastroenterology Unit, "Papardo Piemonte" Hospital, Messina, Italy.
Inflamm Bowel Dis ; 2022 Apr 06.
Article in English | MEDLINE | ID: covidwho-2232823
ABSTRACT

BACKGROUND:

Data from the first wave of the coronavirus disease 2019 (COVID-19) pandemic suggested that patients with inflammatory bowel disease (IBD) are not at higher risk of being infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population and that a worse prognosis is not associated with immunomodulatory drugs, with the possible exception of systemic steroids.

METHODS:

This retrospective, observational study included consecutive IBD patients from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) cohort who had a SARS-CoV-2 infection diagnosis (polymerase chain reaction-confirmed presence of the viral genome in a nasopharyngeal swab) during the second COVID-19 pandemic wave (September 2020 to December 2020). Data regarding demographics, IBD features and treatments, and comorbidities were analyzed in correlation with COVID-19 clinical outcomes.

RESULTS:

Data on 122 patients (mean age, 43.9 ±â€…16.7 years; males, 50.0%; Crohn's disease, 62.3%; ulcerative colitis, 37.7%) were reported. Twelve patients developed COVID-19-related pneumonia (9.8%), 4 (3.3%) required respiratory assistance (nonmechanical ventilation or orotracheal intubation), and 4 died (case fatality rate, 3.3%). In a multivariable analysis, age (odds ratio [OR], 1.034; 95% CI, 1.006-1.147; P = .032) and severe IBD activity (OR, 13.465; 95% CI, 1.104-164.182; P = .042) were independent predictors of COVID-19-related pneumonia, while severe IBD activity (OR, 15.359; 95% CI, 1.320-178.677; P = .030) was the only independent predictor of severe COVID-19, a composite endpoint defined as the need for respiratory assistance or death. A trend towards a protective role of tumor necrosis factor α inhibitors on pneumonia development was reported (P = .076).

CONCLUSIONS:

In this cohort of patients with IBD and SARS-CoV-2 infection, severe IBD activity was the only independent risk factor for severe COVID-19.
This retrospective, observational study on patients with inflammatory bowel disease and severe acute respiratory syndrome coronavirus 2 infection showed that severe inflammatory bowel disease activity was the only independent risk factor for severe coronavirus disease 2019.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal subject: Gastroenterology Year: 2022 Document Type: Article Affiliation country: Ibd

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal subject: Gastroenterology Year: 2022 Document Type: Article Affiliation country: Ibd